Vonoprazan
Clinical data | |
---|---|
Trade names | Takecab |
ATC code |
|
Pharmacokinetic data | |
Bioavailability | Unknown |
Protein binding | 80% |
Metabolism | Hepatic, by cytochrome P450 (3A4, 2B6, 2C19, 2D6) |
Elimination half-life | 7.7 h |
Duration of action | > 24 h |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C17H16FN3O2S |
Molar mass | 345.39 g·mol−1 |
3D model (JSmol) | |
| |
|
Vonoprazan (trade name Takecab) is a first-in-class potassium-competitive acid blocker. It was approved in the Japanese market in February 2015.[1]
Vonoprazan is used in form of the fumarate for the treatment of gastroduodenal ulcer (including some drug-induced peptic ulcers) and reflux esophagitis, and can be combined with antibiotics for the eradication of Helicobacter pylori.[2]
References[]
- ^ Garnock-Jones KP (2015). "Vonoprazan: first global approval". Drugs. 75 (4): 439–43. doi:10.1007/s40265-015-0368-z. PMID 25744862.
- ^ Echizen H (2016). "The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations". Clin Pharmacokinet. 55 (4): 409–18. doi:10.1007/s40262-015-0326-7. PMID 26369775.
Categories:
- Drugs acting on the gastrointestinal system and metabolism
- Proton-pump inhibitors
- Gastrointestinal system drug stubs